Key leanings from the RSV challenge model and efficacy of vaccines

Committee (HREC) to initiate a Phase I trial of CDI-988 for the treatment of Covid-19. CDI-988 is an oral, broad-spectrum 3CL protease inhibitor designed using Cocrystal’s proprietary drug discovery platform technology. The double-blind, randomised, dose-escalating, placebo-controlled study aims to to

Introducing Dr Catchpole As Chief Scientific Officer, Dr Catchpole has “overall responsibility for the scientific conduct” of hVIVO’s studies and laboratory services, and oversees the manufacturing of their challenge viruses. He runs the team that designs the studies

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

IntroductionA small sized pharmaceutical company, who had already performed proof-of-concept studies with a small molecule drug candidate came to Venn Life Sciences with the aim to bring their product into clinic as soon as possible. ChallengesThe company’s first

Pharmaceutical services firm Hvivo, formerly Open Orphan, will pay a dividend to shareholders after a “record financial and operational performance” last year. The Dublin and London-listed organisation is set to pay a one-off special dividend of £3m (€3.4m)

Bruno Speder, VP of regulatory affairs & consultancy services, hVIVO, discusses how Human Challenge Trials (HCT) can be used in the framework of expedited review programs as part of drug and vaccine development. Key insights: hVIVO plc (formerly Open Orphan

The Challenge Malaria is a serious and life-threatening, mosquito borne disease prevalent across much of tropical and sub-tropical Asia, South America and Sub-Saharan Africa. Due to increasing resistance to current antimalarial regimens, new drugs are required as both

Hvivo, formerly known as Open Orphan, has reported a 30 per cent jump in revenue to £50.6 million (€57.2 million) for last year. The Dublin and London-listed pharmaceutical company said bigger contracts with clients drove the size of

Everybody knows what the common cold and influenza are, but we’d guess not many have heard of RSV (Respiratory Syncytial Virus). So, what it is? Well, it is a very common virus that leads to mild, cold like

Chief Scientific Officer, Andrew Catchpole discusses hVIVO’s attendance at the World Vaccine Congress in Washington. hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory

Clinical field studies are a critical part of the drug development and approval process. They are conducted to evaluate the safety, immunogenicity, and efficacy of a new drug. These studies require careful monitoring, attention to detail, significant logistics,

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

hVIVO – a company focused on testing global infectious and respiratory disease products through clinical trials – has recorded positive interim results from its study involving Cidara Therapeutics’ CD388 influenza therapy. hVIVO is currently conducting the wider phase

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services